Inclusion Criteria:

          -  • Patients must be male or female ≥18 years of age

               -  Patients with histologically or cytologically confirmed metastatic adenocarcinoma
                  of the pancreas.

               -  Patients must have tested negative for BRCA 1 or 2 germline deleterious mutation
                  or be ineligible for BRCA testing [as determined by their insurer]

               -  Patients with previously identified Loss of ATM by IHC OR

               -  Family history of BRCA-associated cancers: breast, ovarian, pancreatic, gastric
                  or prostate must be present in 2 or more first-degree relatives OR

               -  Patients with previously identified genetic aberrations that are associated with
                  HRD will be eligible [e.g. somatic BRCA mutation, Fanconi Anemia gene or RAD51
                  mutations].

               -  Patients must have received at least one prior therapy for metastatic disease or
                  have refused chemotherapy to be eligible

               -  Patients with measurable disease and/or non-measurable or no evidence of disease
                  assessed at baseline by CT (or MRI where CT is contraindicated) will be entered
                  in this study. RECIST 1.1 has been modified to allow the assessment of
                  progression due to new lesions in patients with no evidence of disease at
                  baseline

               -  ECOG (Eastern Cooperative Oncology Group: A performance status using scales and
                  criteria to assess how a patient's disease is progressing)Performance Status 0-1
                  (Karnofsky >70).

               -  Patients must have adequate organ and marrow function as defined below:

          -  Leukocytes >3,000 cells/mm3

          -  Absolute neutrophil count >1,500 cells/mm3

          -  Platelets >100,000 cells/mm3

          -  Hemoglobin >9 g/dl (no blood transfusions within 4 weeks prior to enrolment)

          -  Total bilirubin <1.5 X institutional upper limit of normal (IULN)

          -  AST aspartate aminotransferase (SGOT)/ALT Alanine transaminase(SGPT) <2.5 X IULN
             without liver metastasis <5 X IULN for patients with liver metastasis

          -  Creatinine within normal institutional limits OR

          -  Creatinine clearance >60 mL/min/1.73 m2 for patients with creatinine levels above
             institutional normal

               -  INR(international normalized ratio ) <1.5

               -  Women of childbearing potential (defined as not post-menopausal for 12 months or
                  no previous surgical sterilization) and fertile men must agree to use adequate
                  contraception for the duration of study participation. Male subjects must agree
                  to refrain from sperm donation during the study and for 30 days after the last
                  dose of study drugs.

               -  Ability to understand and the willingness to sign a written informed consent
                  document. Signed informed consent form must be obtained prior to initiation of
                  study evaluations and/or activities.

        Exclusion Criteria:

          -  Uncontrolled intercurrent illness including symptomatic congestive heart failure,
             unstable angina pectoris, cardiac arrhythmia and myocardial infarction (MI) within 3
             months of initiation of therapy.

               -  Pregnancy or lactation

               -  Patient has active and uncontrolled bacterial, viral, or fungal infection(s)
                  requiring systemic therapy

               -  Patient has undergone major surgical resection within 4 weeks prior to
                  enrollment.

               -  Patient received radiotherapy, surgery, chemotherapy, or an investigational
                  therapy within 2 weeks prior to study entry.

               -  Patient has serious medical risk factors involving any of the major organ systems
                  such that the investigator considers it unsafe for the patient to receive an
                  experimental research drug

               -  Serious psychiatric or medical conditions that could interfere with treatment

               -  History of prior malignancy unless the malignancy has been treated with no
                  evidence of active disease and more than 2 years from initial diagnosis

               -  Major bleeding in the last 4 weeks prior to study entry